Angiogenesis and antiangiogenic therapy in hematologic malignancies
| Autor: | Xunwei Dong, Zhongchao Han, Renchi Yang |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Poor prognosis
Pathology medicine.medical_specialty biology Neovascularization Pathologic Angiogenesis business.industry VEGF receptors Antiangiogenic therapy Angiogenesis Inhibitors Antineoplastic Agents Hematology Angiogenesis inhibitor Neovascularization Oncology Hematologic Neoplasms Cancer research biology.protein Overall survival Medicine Animals Humans medicine.symptom business |
| Zdroj: | Critical reviews in oncology/hematology. 62(2) |
| ISSN: | 1040-8428 |
| Popis: | Angiogenesis, the generation of new blood capillaries from preexisting blood vessels, is tightly regulated in the adult organism. Although many of the initial studies were performed on solid tumors, increasing evidence indicates that angiogenesis also plays an important role in hematologic malignancies. Overexpression of angiogenic factors in particular VEGF and bFGF in most hematologic malignancies may explain the increased angiogenesis found in these malignancies and correlate with poor prognosis as well as decreased overall survival. In this review, we focus on the current literature of angiogenesis and antiangiogenic therapy in hematologic malignancies, and finally describe advances and potential challenges in antiangiogenic treatment in hematologic malignancies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect